AUTOLUS THERAPEUTICS P

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

08 11 2024 15:23:24 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

05 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

28 10 2024 16:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

16 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

19 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

27 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

08 8 2024 06:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

26 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

31 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

17 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

13 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

24 4 2024 09:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

23 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

02 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Changes to its Board of Directors

01 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

14 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

12 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Blood Cancer Journal

11 3 2024 06:00:00 提供 Nasdaq GlobeNewswire